Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Equivalents (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash & Equivalents for 16 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a N/A change, with the full-year FY2025 number at $405000.0, down 66.19% from a year prior.
  • Cash & Equivalents was $1.1 million for Q3 2025 at IGC Pharma, up from $454000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $13.3 million in Q2 2021 to a low of $405000.0 in Q1 2025.
  • A 5-year average of $3.9 million and a median of $2.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 392.75% in 2021, then crashed 75.79% in 2023.
  • IGC Pharma's Cash & Equivalents stood at $13.3 million in 2021, then tumbled by 62.87% to $4.9 million in 2022, then crashed by 36.83% to $3.1 million in 2023, then crashed by 84.96% to $470000.0 in 2024, then surged by 135.11% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash & Equivalents are $1.1 million (Q3 2025), $454000.0 (Q2 2025), and $405000.0 (Q1 2025).